Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2022; 12(02): 134-138
DOI: 10.1055/s-0041-1736274
Original Article

A Study on the Effect of Valeric Acid in Alzheimer's Induced Rats by the Estimation of Aβ 1-42 Biomarker

Blessina Sugandhi Dulla
1   Department of Anatomy, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India
,
Bindhu S.
1   Department of Anatomy, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India
,
Leena Pramod K.
2   Department of Forensic Medicine and Toxicology, Yenepoya Medical College, Yenepoya (deemed to be) University, Mangalore, Karnataka, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The effect of valeric acid on the behavior of Alzheimer's disease (AD)-induced rats by aluminum chloride (100 mg/kg body weight) was assessed using elevated plus maze (EPM) and the Hebb Williams maze (HWM). Amyloid β 1–42(Aβ1–42) biomarker was estimated by ELISA. In this study, valeric acid-treated rats were compared with those treated with piracetam (200 mg/kg), rivastigmine (0.5 mg/kg), and the results showed the rats treated with valeric acid had a very less transfer latency of EPM and HWM when compared with other standard drugs. In addition, valeric acid-treated rats showed reduced levels of amyloid β1–42 biomarker in the plasma. Hence, this study found that valeric acid may be suggested as a better drug for Alzheimer's disease.

Keywords

Alzheimer's disease - amyloid β 1–42 - elevated plus maze - Hebb Williams maze - valeric acid


Publication History

Article published online:
24 October 2021

© 2021. Nitte (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rahman H, Shaik HA, Madhavi P, Eswaraiah MC. A review: pharmacognostics and pharmacological profiles of Nardastachys jatamansi DC. Elixir Pharmacy 2011; 39: 5017-5020
    Google Scholar
  • 2 Achliya G, Barabde U, Wadodkar S, Dorlel A. Effect of Bramhi Ghrita, an polyherbal formulation on learning and memory paradigms in experimental animals. Indian J Pharmacol 2004; 36 (03) 159-162
    Google Scholar
  • 3 Hassan SK, Mandal US, Mondal DK, Jana D. A study on stress, anxiety and depression among caregivers of the patients with dementia in a tertiary care hospital in eastern India. Int J Sci Res 2020; 9 (01) 7-9
    Google Scholar
  • 4 Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res 2012; 3 (04) 200-201
    CrossrefPubMedGoogle Scholar
  • 5 Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67 (08) 1755-1758
    PubMedGoogle Scholar
  • 6 Eadie MJ. Could valerian have been the first anticonvulsant?. Epilepsia 2004; 45 (11) 1338-1343
    CrossrefPubMedGoogle Scholar
  • 7 Krystal AD, Ressler I. The use of valerian in neuropsychiatry. CNS Spectr 2001; 6 (10) 841-847
    CrossrefPubMedGoogle Scholar
  • 8 Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24 (11) 1373-1378
    CrossrefPubMedGoogle Scholar
  • 9 Neamati A, Chaman F, Hosseini M, Boskabady MH. The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats. J Pharm Bioallied Sci 2014; 6 (02) 97-103
    CrossrefPubMedGoogle Scholar
  • 10 Luder AS, Parks JK, Frerman F, Parker Jr WD. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest 1990; 86 (05) 1574-1581
    CrossrefPubMedGoogle Scholar
  • 11 Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009; 2 (01) 95-109
    CrossrefPubMedGoogle Scholar
  • 12 Frumkes TE, Nelson R. Functional role of GABA in cat retina: I. Effects of GABAA agonists. Vis Neurosci 1995; 12 (04) 641-650
    CrossrefPubMedGoogle Scholar
  • 13 Ahmad Rather M, Justin Thenmozhi A, Manivasagam T, Dhivya Bharathi M, Essa MM, Guillemin GJ. Neuroprotective role of asiatic acid in aluminium chloride induced rat model of Alzheimer's disease. Front Biosci (Schol Ed). 2018; 10: 262-275
    PubMedGoogle Scholar
  • 14 Bhattacharjee S, Zhao Y, Hill JM, Percy ME, Lukiw WJ. Aluminum and its potential contribution to Alzheimer's disease (AD). Front Aging Neurosci 2014; 6: 62
    CrossrefPubMedGoogle Scholar
  • 15 Exley C. What is the risk of aluminium as a neurotoxin?. Expert Rev Neurother 2014; 14 (06) 589-591
    CrossrefPubMedGoogle Scholar
  • 16 Oshima E, Ishihara T, Yokota O. et al. Accelerated tau aggregation, apoptosis and neurological dysfunction caused by chronic oral administration of aluminum in a mouse model of tauopathies. Brain Pathol 2013; 23 (06) 633-644
    CrossrefPubMedGoogle Scholar
  • 17 Fessel J. Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs. Alzheimers Dement (N Y) 2019; 5: 780-788
    CrossrefPubMedGoogle Scholar
  • 18 Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011; 6 (07) e21954
    CrossrefPubMedGoogle Scholar
  • 19 Copanaki E, Chang S, Vlachos A. et al. sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Mol Cell Neurosci 2010; 44 (04) 386-393
    CrossrefPubMedGoogle Scholar
  • 20 Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993; 35 (05) 567-576
    CrossrefPubMedGoogle Scholar
  • 21 Charan J, Kantharia ND. How to calculate sample size in animal studies?. J Pharmacol Pharmacother 2013; 4 (04) 303-306
    CrossrefPubMedGoogle Scholar
  • 22 Vishwakarma S, Goyal R, Gupta V, Dhar KL. GABAergic effect of valeric acid from Valerianawallichii in amelioration of ICV STZ induced dementia in rats. Rev Bras Farmacogn 2016; 26 (04) 484-489
    CrossrefGoogle Scholar
  • 23 Varma RK, Singh L, Garg VK, Yadav P, Singh VK. Nootropic effect of vigna mungo (l.) hepper seeds extract in scopolamine induced amnesic rats. World J Pharm Sci 2016; 5 (12) 1176-1192
    Google Scholar
  • 24 Gawel K, Labuz K, Gibula-Bruzda E. et al. Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn Schmiedebergs Arch Pharmacol 2016; 389 (10) 1059-1071
    CrossrefPubMedGoogle Scholar
  • 25 Abramets II, Kuznetsov YV, Evdokimov DV, Zaika TO. Piracetam potentiates neuronal and behavioral effects of ketamine. Res Pharmacol 2019; 5 (02) 49-55
    Google Scholar
  • 26 Deepa B, Divya B, Kumari NS, Sanjeev G, Rao S. Effect of electron beam radiations on memory in experimental animal models. Drug Invention Today 2012; 4 (09) 444-446
    Google Scholar
  • 27 Vasudevan M, Parle M. Effect of Anwala churna (Emblica officinalis GAERTN.): an ayurvedic preparation on memory deficit rats. Yakugaku Zasshi 2007; 127 (10) 1701-1707
    CrossrefPubMedGoogle Scholar
  • 28 Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120 (03) 885-890
    CrossrefPubMedGoogle Scholar
  • 29 Lin WT, Chen RC, Lu WW, Liu SH, Yang FY. Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model. Sci Rep 2015; 5: 9671 DOI: 10.1038/srep09671.
    CrossrefPubMedGoogle Scholar
  • 30 Thippeswamy AH, Rafiq M, Viswantha GLS, Kavya KJ, Anturlikar SD, Patki PS. Evaluation of Bacopa monniera for its synergistic activity with rivastigmine in reversing aluminum-induced memory loss and learning deficit in rats. J Acupunct Meridian Stud 2013; 6 (04) 208-213
    CrossrefPubMedGoogle Scholar
  • 31 Auti ST, Kulkarni YA. Neuroprotective effect of cardamom oil against aluminum induced neurotoxicity in rats. Front Neurol 2019; 10: 399
    CrossrefPubMedGoogle Scholar
  • 32 Matsubara E, Ghiso J, Frangione B. et al. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 1999; 45 (04) 537-541
    CrossrefPubMedGoogle Scholar
  • 33 Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60 (07) 958-964
    CrossrefPubMedGoogle Scholar
  • 34 Liu HC, Chiu MJ, Lin CH, Yang SY. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dement Geriatr Cogn Disord Extra 2020; 10 (01) 46-55
    CrossrefPubMedGoogle Scholar